Multiple host range bacteriophage with hybrid tail fibres
AssigneePhico Therapeutics Ltd.
InventorsHeather FAIRHEAD, Adam WILKINSON, Katy PITTS, Anne BARNARD, Emmanuele SEVERI, Neil ANDERSON
Life of this patent
Estimating the term…
Abstract
Modified bacteriophage, uses thereof, and compositions containing the modified bacteriophage are described. The compositions are useful for human treatment and may treat various conditions, including bacterial infections.
Claims21
1-38. (canceled)
A modified bacteriophage capable of infecting a plurality of different target bacteria, wherein:
- (a) said bacteriophage includes an α/β small acid-soluble spore protein (SASP) gene encoding a SASP which is toxic to the target bacteria;
- (b) said bacteriophage expresses a single hybrid host range determinant protein which comprises an amino acid sequence derived from amino acid sequences of range determinant proteins from at least two different bacteriophages, and
- (c) said hybrid host range determinant protein is a tail fiber protein,
- (d) wherein said hybrid host range determinant protein comprises an N-terminal region wherein said N-terminal region binds to the body of said bacteriophage and a C-terminal region wherein said C-terminal region comprises a receptor binding region for binding to the target bacteria and wherein the amino acid sequence of said N-terminal region of said hybrid host range determinant protein is derived from a different bacteriophage than the amino acid sequence of said C-terminal region.
A modified bacteriophage according to claim 49, wherein the lysis gene is inactivated by insertion of said SASP gene.
A modified bacteriophage according to claim 51, wherein the SASP-C is from Bacillus megaterium.
Dependencies are inferred from the claim text.